BETHLEHEM, Pa., April 28, 2011 /PRNewswire/ — Particle Sciences
Inc. (PSI), a leading pharmaceutical CRO, and Celanese EVA
Performance Polymers, a leading supplier of ethylene vinyl acetate
(EVA) into pharmaceutical applications, are working together to
streamline the development of drug-eluting devices. Building
on years of collaboration, Particle Sciences and Celanese EVA
Performance Polymers are working to provide Particle Sciences with
preferred access to VitalDose™ EVA polymer in early stage
projects.
According to Andrew Loxley, Particle Sciences’ Director of New
Technologies, “With combination products, devices that deliver
drugs, there are multiple parties involved including the innovator,
the API supplier, the development group and the polymer supplier.
All parties want to ensure a quality product. Particle
Sciences and Celanese EVA Performance Polymers have been
collaborating for a number of years and, because of that
relationship, are now in a position to expedite the process.”
With this collaboration, there is a highly streamlined process
by which Particle Sciences obtains access to use Celanese EVA
polymers in early development efforts. Jamie Beggs, Marketing
Development Manager, Celanese EVA Performance Polymers, states, “We
are committed to becoming the premier EVA excipient producer and
have been providing EVA technology for medical applications for
years. Our VitalDose brand delivers the reliable performance
required for pharma applications combined with in-depth technical
expertise and comprehensive regulatory knowledge. This
partnership is a testament to the degree to which we have developed
confidence in Particle Sciences’ capabilities and their focus on
quality. With their capabilities in prototyping,
characterization, experience with controlled and highly potent
substances and cGMP facilities, they have consistently delivered
innovation to our customers.”
Robert Lee
‘/>”/>